SLS shares jump 12% on looming trial data, buyout hints

Sellas Life Sciences Group Inc. (NASDAQ: SLS) shares jumped 12.26% to close at $13.19 on Friday as traders aggressively positioned for a critical clinical trial readout. The sharp rally was driven by the imminent release of Phase 3 data and fresh market speculation surrounding a potential acquisition of the biotech firm.

The primary catalyst for the price action is the looming overall survival data for Galinpepimut-S, an experimental treatment for acute myeloid leukemia. The study's statistical success relies on a pre-specified endpoint of 80 patient deaths to compare the drug's efficacy against a placebo. Sellas recently confirmed it has already recorded its 78th death, placing the final data release just weeks away. A positive result would validate the therapy and fundamentally reshape the company's clinical and financial trajectory.

This investor enthusiasm was further compounded by recent regulatory filings that hinted at possible behind-the-scenes corporate action. Last month, Sellas amended the employment and severance agreements for President and CEO Angelos Stergiou, Chief Financial Officer John Burns, and Chief Development Officer Dragan Cicic. The updated contracts feature specific "change of control" provisions that stand out to market observers.

Under these revised terms, Burns and Cicic are positioned to receive lump-sum payments equal to 15 months of their base salary, their target annual bonus, and the immediate vesting of unvested equity if a new owner decides not to retain them. While the company has not publicly announced a sale process, investors are actively interpreting these governance changes as standard preparatory steps for a potential takeover.

Institutional investors appear willing to shoulder the risk ahead of this binary event. Data from Insider Monkey shows the number of hedge funds holding SLS shares doubled to 13 in the first quarter, up from just six in the fourth quarter of 2025. The collective value of these institutional positions climbed to $13.49 million from $10.8 million over the same period.

For market professionals, SLS has transitioned into a pure event-driven trade. The stock's recent momentum reflects a market attempting to price in both clinical success and a strategic buyout premium. However, with the trial endpoint rapidly approaching, the stock faces severe volatility that will ultimately be dictated by the upcoming survival data.